Sonoma Pharmaceuticals Stock Market Value
| SNOA Stock | USD 2.79 0.13 4.45% |
| Symbol | Sonoma |
Sonoma Pharmaceuticals Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.99) | Revenue Per Share 20.967 | Quarterly Revenue Growth (0.01) | Return On Assets (0.20) | Return On Equity (0.75) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Sonoma Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sonoma Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sonoma Pharmaceuticals.
| 11/01/2024 |
| 12/01/2024 |
If you would invest 0.00 in Sonoma Pharmaceuticals on November 1, 2024 and sell it all today you would earn a total of 0.00 from holding Sonoma Pharmaceuticals or generate 0.0% return on investment in Sonoma Pharmaceuticals over 30 days. Sonoma Pharmaceuticals is related to or competes with China Pharma, Universe Pharmaceuticals, Akanda Corp, Petros Pharmaceuticals, Sunshine Biopharma, Alpha Teknova, and Cannara Biotech. Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid products for wound care, animal health ... More
Sonoma Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sonoma Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sonoma Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 6.43 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 40.82 | |||
| Value At Risk | (10.93) | |||
| Potential Upside | 13.88 |
Sonoma Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sonoma Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sonoma Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Sonoma Pharmaceuticals historical prices to predict the future Sonoma Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0122 | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (1.22) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0104 |
Sonoma Pharmaceuticals Backtested Returns
Sonoma Pharmaceuticals appears to be dangerous, given 3 months investment horizon. Sonoma Pharmaceuticals owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0329, which indicates the firm had a 0.0329% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Sonoma Pharmaceuticals, which you can use to evaluate the volatility of the company. Please review Sonoma Pharmaceuticals' Coefficient Of Variation of 23308.27, risk adjusted performance of 0.0122, and Semi Deviation of 5.93 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Sonoma Pharmaceuticals holds a performance score of 2. The entity has a beta of 2.09, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sonoma Pharmaceuticals will likely underperform. Please check Sonoma Pharmaceuticals' semi variance, and the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether Sonoma Pharmaceuticals' existing price patterns will revert.
Auto-correlation | 0.21 |
Weak predictability
Sonoma Pharmaceuticals has weak predictability. Overlapping area represents the amount of predictability between Sonoma Pharmaceuticals time series from 1st of November 2024 to 16th of November 2024 and 16th of November 2024 to 1st of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sonoma Pharmaceuticals price movement. The serial correlation of 0.21 indicates that over 21.0% of current Sonoma Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.21 | |
| Spearman Rank Test | -0.14 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Sonoma Pharmaceuticals lagged returns against current returns
Autocorrelation, which is Sonoma Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Sonoma Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of Sonoma Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that Sonoma Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Sonoma Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Sonoma Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Sonoma Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Sonoma Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
Sonoma Pharmaceuticals Lagged Returns
When evaluating Sonoma Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Sonoma Pharmaceuticals stock have on its future price. Sonoma Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Sonoma Pharmaceuticals autocorrelation shows the relationship between Sonoma Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in Sonoma Pharmaceuticals.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out Sonoma Pharmaceuticals Correlation, Sonoma Pharmaceuticals Volatility and Sonoma Pharmaceuticals Alpha and Beta module to complement your research on Sonoma Pharmaceuticals. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Sonoma Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.